Do we need a different set of response assessment criteria for tumor immunotherapy?
Tumor shrinkage induced by tumor immunotherapy may be preceded by inflammatory changes. This confounds the assessment of response rates to tumor immunotherapy. In this issue of Clinical Cancer Research, Wolchok et al. attempt to address this peculiarity by proposing a new set of criteria termed immune-related response criteria.
Ribas
Antoni
A
Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, California 90095-1782, USA. aribas@mednet.ucla.edu
Chmielowski
Bartosz
B
Glaspy
John A
JA
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007249:Inflammation / Q000473:pathology; D000074324:Ipilimumab; D008495:Medical Oncology / Q000592:standards; D008954:Models, Biological; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000074324:Ipilimumab